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Treatment outcomes of acute leukemia (AL) have not improved over the past several decades and relapse rates remain high 
despite the availability of aggressive therapies. Conventional relapsed leukemia treatment includes second allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI), which in most cases mediate, at best, a 
modest graft-versus-leukemia effect, although their clinical efficacy is still limited. Although allo-HSCT following myeloabla-
tive conditioning is a curative treatment option for younger patients with acute myeloid leukemia (AML) in a first complete 
remission (CR), allo-HSCT as a clinical treatment is usually limited because of treatment-related toxicity. The overall DLI re-
mission rate is only 15%–42% and 2-year overall survival (OS) is approximately 15%–20%, with a high (40%–60%) incidence 
of DLI-related graft-versus-host disease (GVHD). Therefore, development of new, targeted treatment strategies for relapsed 
and refractory AL patients is ongoing. Adoptive transfer of T cells with genetically engineered chimeric antigen receptors 
(CARs) is an encouraging approach for treating hematological malignancies. These T cells are capable of selectively recog-
nizing tumor-associated antigens and may overcome many limitations of conventional therapies, inducing remission in patients 
with chemotherapy-refractory or relapsed AL. In this review, we aimed to highlight the current understanding of this promising 
treatment modality, discussing its adverse effects and efficacy. 
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Allo-HSCT and chemotherapy have been used to success-
fully treat patients with acute lymphoblastic leukemia 
(ALL), but the prognosis of adult patients with relapsed 
ALL is still very poor. Long-term survival rate of adult pa-
tients with relapsed ALL depends on the achievement of 
CR, induced through chemotherapy, followed by allo-HSCT 
(Fielding et al., 2007; Gokbuget et al., 2012). Unfortunately, 
many patients will not receive allo-HSCT because of a fail-
ure in achieving second CR following salvage chemothera-
py. For patients with AML, the probability of being cured 
with chemotherapy alone is significantly lower than com-
bined treatment, as only 50%–65% patients achieve long- 
term survival (Gibson et al., 2005; Lange et al., 2008; 
Creutzig et al., 2008). Moreover, the prognosis is even 
worse in elderly patients (Kaspers et al., 2006; Appelbaum 
et al., 2006).To address the problem of limited therapeutic 
success of treating relapsed/refractory ALL or AML, adop-
tive therapy with chimeric antigen receptor expressing T 
(CAR-T) cells is a promising approach for hematologic ma-
lignancies. 
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CAR: GENETICALLY MODIFIED ADOPTIVE 
CELL THERAPY 
CAR-T cells were first described as an adoptive cell therapy 
in 1989 by Gross and colleagues (Gross et al., 1989). CARs 
are composed of an extracellular domain that recognizes 
tumor surface antigens and is linked to an intracellular sig-
naling domain via trans-membrane domains. The extracel-
lular domain consists of antigen-binding variable regions 
from monoclonal antibody heavy and light chains that are 
fused into a single protein known as the single-chain varia-
ble fragment (Dotti et al., 2014; Jena et al., 2010). First- 
generation CAR contained a single-signaling domain de-
rived from either TCR-ζ or FcR-γ chain (Eshhar et al., 
1993; Moritz et al., 1994). Second-generation CAR includ-
ed a single co-stimulatory domain derived from either 4- 
1BB or CD28. Third-generation CAR had two co-stimula- 
tory domains, namely 4-1BB and CD28, and other co-stim- 
ulatory molecules (Goker et al., 2016). T cell genetic modi-
fication with CAR has several advantages in leukemia 
treatment, e.g., CAR use is applicable to a broad range of 
patients irrespective of the HLA phenotype. CAR-T cell 
approach also overcomes ability of the tumor to escape 
immunosurveillance by down-regulating HLA molecules on 
cell surface. Targeting of tumor antigens with CAR-T cells 
is applicable to any tumor antigens, including glycolipids, 
proteins, and carbohydrates. CAR-T cell clinical trials are 
currently conducted. 
ONGOING TRIALS OF TREATING AL 
PATIENTS WITH CAR-T CELLS 
Until now, 30 CAR-T AL trials have been published. Some 
of these focused on ALL, targeting CD19 or CD20, whereas 
others focused on AML, targeting Lewis-Y antigen or 
CD33. The results are summarized in Table 1. 
PUBLISHED CLINICAL OUTCOMES OF 
ADOPTIVE THERAPY WITH CAR-MODIFIED 
T CELLS FOR ALL 
Relapsed ALL is difficult to treat despite the availability of 
aggressive therapies. Promising results have been obtained 
in recent studies on CD19/CD20-targeted CAR-T (CD19/ 
CD20-CAR-T) for ALL treatment (Kochenderfer et al., 
2012). Maude and colleagues conducted research into in-
fusing autologous T cells transduced with CD19-targeted 
CAR (CD19-CAR-T) in patients with relapsed or refractory 
ALL. Patients were monitored for clinical response and 
toxic effects. The clinical results revealed that CR was 
achieved in 27 (90%) out of 30 patients (children and 
adults). Sustained remission was achieved, with 67% 
6-month event-free survival rate and 78% OS rate. Cyto-
kine-release syndrome (CRS), which later developed in 
27% patients, was associated with a higher disease burden. 
Davila and colleagues examined 16 patients with relapsed 
or refractory B cell acute lymphoblastic leukemia (B-ALL) 
who were treated with CD19-CAR-T. Clinical results re-
vealed 88% overall complete response rate. This therapy 
was as effective in treating high-risk patients with Phila-
delphia chromosome-positive Ph+ disease, as in treating 
those with relapsed disease after previous allo-HSCT 
(Davila et al., 2014). Shortly afterwards, Lee and colleagues 
published outcomes of a clinical investigation concerning 
21 patients with relapsed or refractory ALL (including eight 
who had previously undergone allo-HSCT) who were in-
fused with CD19-CAR-T. Safety of the treatment was eval-
uated and any toxic effects were fully reversible, with the 
highest severity, Grade 4, CRS observed in 3 (14%) out of 
21 patients (95% CI 3.0–36.3) (Lee et al., 2015). Thus, 
CD19-CAR-T therapy is feasible, safe, and mediates a po-
tent anti-leukemic effect in patients with ALL.  
PUBLISHED CLINICAL OUTCOMES OF 
ADOPTIVE THERAPY WITH CAR-MODIFIED 
T CELLS FOR AML 
Despite the improvement in allo-HSCT and chemothera-
py-based treatment of AML, the majority of standard or 
high-risk AML patients will die or relapse. AML is sensi-
tive to T-cell-mediated control in the allo-HSCT setting. 
Nevertheless, therapeutic approaches directed at inducing 
autologous T-cell responses in patients have shown limited 
efficacy (Wen et al., 2002; Kershaw et al., 2006). Therefore, 
the development of novel therapeutics for treating AML is 
crucial. Although CD19-CAR-T approaches are proving 
highly effective against hematologic malignancies (Brenner 
et al., 2013), a concern has been raised that extending this 
success to other tumors may be difficult. CD19 antigen 
(Jensen et al., 2010) is generally restricted to the B cell lin-
eage. In contrast, LeY antigen is a difucosylated carbohy-
drate antigen widely expressed by AML cells, but with a 
limited expression in healthy tissues. However, its role and 
significance for the survival of leukemia cells remain to be 
elucidated. In 2013, a phase I clinical trial was conducted at 
the Ludwig Institute for Cancer Research (Ritchie et al., 
2013) examining autologous CAR-anti-LeY-T therapy for 
AML. Safety and post-infusion persistence of adoptively 
transferred T cells. Neither Grade 3 nor Grade 4 toxicities 
were observed. One patient achieved a cytogenetic remis-
sion whereas in another, with active leukemia, reduction in 
peripheral blood (PB) blasts was observed. This clinical 
outcome verified the safety and feasibility of CAR-T thera-
py in high-risk AML patients and demonstrated durable in 
vivo persistence. CD123, a trans-membrane chain of inter-
leukin (IL)-3 receptor, is expressed in the majority of AML 
cells and in many normal cells. Recent preclinical reports 
have demonstrated that CAR-T cells have the potential to 
effectively and durably eradicate primitive myeloid blast 
cells (Mardiros et al., 2013). Mardiros and colleagues con- 
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Table 1  Summary of ongoing clinical trials of autologous/allogeneic CAR-T cell treatments for AL 
Disease Target antigen Gene transfer CAR signaling domain Sponsor Clinical Trial.gov 
ID 
Status 
ALL CD20 Retrovirus scFv-(4-1BB–CD3ζ) Chinese PLA General Hospital NCT01735604 Recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) Penn Medicine’s Abramson Cancer 
Center 
NCT00891215 Completed 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) University of Pennsylvania NCT01551043 Completed 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Baylor College of Medicine NCT00608270 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Memorial Sloan KetteringCancer Center NCT01416974 Recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) University of Pennsylvania NCT02030847 Recruiting 
ALL CD19 Lentivirus scFv-(CD3ζ) Fred Hutchinson Cancer 
Research Center 
NCT01475058 Completed 
ALL CD19 Lentivirus scFv-(CD3ζ) Fred Hutchinson Cancer Research Center NCT01865617 Recruiting 
ALL CD19 Lentivirus scFv-(CD28-CD3ζ) City of Hope Medical Center NCT02146924 Recruiting 
AML CD123 Lentivirus scFv-(CD28-CD3ζ) City of Hope Medical Center NCT02159495 Recruiting 
ALL CD19 Retrovirus 
scFv-(CD28-CD3ζ& 
CD28-CD137-CD3ζ) Baylor College of Medicine NCT01853631 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Memorial Sloan Kettering 
Cancer Center 
NCT01840566 Recruiting 




Memorial Sloan Kettering 
Cancer Center 
NCT00466531 Recruiting 
ALL CD19 Retrovirus scFv-(CD3ζ) University College London NCT01195480 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Memorial Sloan Kettering Cancer Center NCT01860937 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ–4-1BB) Uppsala University NCT02132624 Recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) Seattle Children’s Hospital NCT02028455 Recruiting 
ALL CD19 Retrovirus scFv-(CD137-CD3ζ ) Chinese PLA General Hospital NCT01864889 Recruiting 
ALL CD19 Transposon scFv-(CD3ζ) MD Anderson Cancer Center NCT01497184 Active, not 
recruiting 
ALL CD19 Retrovirus scFv-(CD3ζ) National Cancer Institute NCT01593696 Recruiting 
AML Lewis-Y Retrovirus scFv-(CD28-CD3ζ) Peter MacCallum Cancer Center NCT01716364 Unknown 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) National Cancer Institute NCT00924326 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Memorial Sloan Kettering 
Cancer Center 
NCT01044069 Recruiting 
ALL CD19 Retrovirus scFv-(CD3ζ) Memorial Sloan Kettering Cancer Center NCT01430390 Recruiting 
AML CD33 Retrovirus scFv-(CD137-CD3ζ) Chinese PLA General Hospital NCT01864902 Recruiting 
ALL CD19 Lentivirus scFv-(CD28-CD3ζ) Seattle Children’s Hospital NCT01683279 Recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) University of Pennsylvania NCT01747486 Recruiting 
ALL CD19 Retrovirus scFv-(CD28-CD3ζ) Baylor College of Medicine NCT00586391 Active, not 
recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) University of Pennsylvania NCT01626495 Recruiting 
ALL CD19 Lentivirus scFv-(4-1BB–CD3ζ) University of Pennsylvania NCT01029366 Completed 
ALL CD19 Retrovirus scFv-(CD3ζ) Baylor College of Medicine NCT00840853 Recruiting 
ALL CD19 Transposon scFv-(CD3ζ) MD Anderson Cancer Center NCT01362452 Active, not 
recruiting 
 
ducted preclinical trials using autologous T cells transduced 
with CD123-targeted CAR (CD123-CAR-T) in infused 
AML xenograft model. Their data revealed a CD123-CAR- 
T-mediated potent activity against CD123+ cell lines as well 
as primary AML samples. Additionally, CD123-CAR-T 
cells exhibited anti-leukemic activity in vivo in a xenogene-
ic AML model. Gill and colleagues suggested that 
CAR-T123-based myeloablation might be used as a novel 
conditioning regimen for hematopoietic cell transplantations 
(Gill et al., 2014). 
DISCUSSION  
A series of clinical trials point to key factors, including 
CAR-T cell design, different gene transfer approaches, and 
tumor burden, that impact efficacy of the CAR-T cell treat-
ment of hematologic malignancies. Preclinical studies and 
clinical trials have demonstrated the advantage of CAR-T 
cell in vivo antitumor activity, enhanced by second- and 
third-generation CAR containing T cell co-stimulatory sig-
naling domains, when compared with first-generation CAR  
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(Brentjens et al., 2007; Teng et al., 2004). For example, 
2014 work of Maude and colleagues (Maude et al., 2014) on 
second-generation CAR-T cells and ALL treatment, 
demonstrated superiority of this approach compared with 
earlier first-generation CAR-T cell experiments Further-
more, most investigators have been attempting different T 
cell gene transfer techniques influencing the efficacy of 
CAR-T cell applications. Retroviruses have been frequently 
used in ALL research because they efficiently and perma-
nently transduce T cells, and preliminarily studies verified 
safety of this approach (Scholler et al., 2012). Lentiviral 
vectors also efficiently transduce T cells but are expensive 
to manufacture, yet potentially safer than retroviruses (Biffi 
et al., 2011). Investigators have seldom resorted to electro-
poration or transposon gene transfer technologies (Jin et al., 
2011; Till et al., 2008). Alas, no published clinical studies 
directly compare the different gene transfer approaches, 
leaving open the question of whether clinically meaningful 
differences exist between these gene transfer vectors. Tu-
mor burden was demonstrated to be yet another important 
factor in CAR-T efficacy in a 2011 study by Memorial 
Sloan-Kettering Cancer Center, where an inverse correla-
tion was noted between tumor burden and the detectable 
infused modified T cells over time (Brentjens et al., 2011). 
Most trials focused on the protocols of allo-HSCT in com-
bination with CAR-T cells, superior to CAR-T cell ap-
proach alone, until 2014, when Maus and colleagues hy-
pothesized that CAR-T cells may replace allogeneic trans-
plantation as a definitive therapy. Maude has published re-
sults of a clinical trial that verified this hypothesis (Maude 
et al., 2014): the event-free survival and OS of ALL patients 
who had previously undergone stem-cell transplantation 
were not different after CAR-T cell treatment than in ALL 
patients who have not received stem-cell transplantation. 
Integration of CAR-T with allo-HSCT in future treatment 
protocols is worth considering, and CAR-T and allo-HSCT 
timings are expected to be verified by future large sample 
randomized trials. CRS is also noteworthy. Investigators 
have shown that CRS was often accompanied by macro-
phage activation syndrome (MAS), which may be driven in 
part by high IL-6 levels (Grupp et al., 2013). In the 
above-mentioned clinical trials, most patients had some 
degree of CRS. It is not yet clear whether the severity of 
CRS or MAS is related to antitumor efficacy. In conclusion, 
CAR-T cell approach has been, undoubtedly, a break-
through in leukemia treatment. Numerous international tri-
als are currently under way to optimize, such as CAR de-
sign, integration protocol optimization, etc. 
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